Intestinal amoebiasis, caused by Entamoeba histolytica, significantly impacts gastrointestinal health. The parasite invades the intestinal lining, leading to inflammation, ulceration, and symptoms such as abdominal pain, diarrhea, and dysentery. Chronic infection may contribute to long-term gastrointestinal disorders, including irritable bowel like symptoms, malabsorption, and increased susceptibility to secondary infections. Understanding these connections helps improve diagnosis and treatment strategies. While metronidazole remains the primary therapy, discussions about antiparasitic access such as sourcing medications through mebendazole wholesale suppliers highlight the importance of affordable treatment options in endemic regions. Effective management and public health measures are essential to reduce complications and transmission.